Aura Biosciences (AURA) insider’s RSU tax sale covers 11,738 shares at ~$7

Rhea-AI Filing Summary

Aura Biosciences, Inc. insider Conor Kilroy reported an open-market sale of 11,738 shares of Common Stock at a weighted average price of about $7.02 per share. According to the disclosure, these shares were sold automatically to cover tax withholding obligations from vested restricted stock units, not at Kilroy’s discretion.

After the sale, Kilroy directly holds 217,835 Aura Biosciences shares, indicating that the transaction reflects a routine tax-related disposition rather than a change in his core ownership position.

Insights

Insider transactions analyst

Routine tax-related sale of a small portion of Aura Biosciences shares.

The filing shows Conor Kilroy selling 11,738 Aura Biosciences common shares at a weighted average of $7.02. Footnotes state the sale was automatic to satisfy tax withholding obligations tied to vesting restricted stock units, not a discretionary trade.

Following the sale, Kilroy still directly owns 217,835 shares, so the transaction represents only a small fraction of his position. Because it is tax-driven and mechanistic, it carries limited informational value about Kilroy’s view of Aura Biosciences (AURA) compared with a typical open-market sale.

Insider Trade Summary

Net Seller: 11,738 shares ($82,401)

Net Sell 1 txn

Insider Kilroy Conor

Role See Remarks

Sold 11,738 shs ($82K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,738	$7.02	$82K

Holdings After Transaction: Common Stock — 217,835 shares (Direct)

Footnotes (1)

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 11,738 shares Weighted average sale price: $7.02 per share Sale price range: $7.02–$7.05 per share +1 more

4 metrics

Shares sold 11,738 shares Open-market sale on tax withholding date

Weighted average sale price $7.02 per share Average price across multiple trades

Sale price range $7.02–$7.05 per share Prices for individual transactions in the sale

Shares held after transaction 217,835 shares Direct Aura Biosciences holdings after the sale

Key Terms

restricted stock units, tax withholding obligations, weighted average price, open-market sale

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required to be sold by the Reporting Person to cover tax withholding obligations"

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kilroy Conor

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		S(1)		11,738	D	$7.02(2)	217,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Legal Officer and Secretary.

	/s/ Conor Kilroy	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aura Biosciences (AURA) insider Conor Kilroy report in this Form 4?

Conor Kilroy reported selling 11,738 shares of Aura Biosciences common stock at a weighted average price of about $7.02 per share. The filing states these shares were sold to cover tax withholding from vested restricted stock units.

Why were Aura Biosciences (AURA) shares sold by Conor Kilroy in this filing?

The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. The footnote explains these sales were automatic and not made at Kilroy’s discretion, indicating a tax-driven, mechanical transaction rather than a voluntary portfolio decision.

How many Aura Biosciences (AURA) shares does Conor Kilroy hold after the reported sale?

After the reported transaction, Conor Kilroy directly holds 217,835 shares of Aura Biosciences common stock. This shows that the 11,738 shares sold for tax withholding represent only a small portion of his overall stake in the company.

What price range applied to the Aura Biosciences (AURA) insider share sale?

The filing reports a weighted average sale price of $7.02 per share, with individual trades executed between $7.02 and $7.05. The company notes it can provide detailed breakdowns of the transactions at each price within this range upon request.

Does this Aura Biosciences (AURA) Form 4 indicate a discretionary insider sale?

The Form 4 describes the sale as an open-market transaction but clarifies it was automatic to meet tax withholding obligations from RSU vesting. Because Kilroy did not choose the sale for investment reasons, it is generally viewed as routine rather than a discretionary reduction.